Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study
Luigi Gargiulo, Luciano Ibba, Matteo Bianco, S. Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Abstract
Dear Editor,The development of biological drugs and small molecules has dramatically changed the therapeutic landscape of moderate-to-severe atopic dermatitis (AD) [1,2]. In particular, Janus Kinas...
Topics & Concepts
MedicineAtopic dermatitisSingle CenterCenter (category theory)DermatologyInternal medicineCrystallographyChemistryDermatology and Skin DiseasesAsthma and respiratory diseasesAllergic Rhinitis and Sensitization